Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Results from an Association-Scan of the Extended MHC-Class-II Region Using Novel Association-Based Statistical Methods Establish That DQ Allotypes and Race Independently Influence the Risk of Factor VIII Inhibitor Development in Hemophilia-A Patients

Paola Ibarra, Marcio A. Almeida, Vincent P. Diego, Bernadette W. Luu, Kevin R. Viel, Raja Rajalingam, Afshin Ameri, Meera Chitlur, Benjamin Kim, Grecia Castillo, Jerry S. Powell, Juan M. Peralta, Miguel A. Escobar, Sarah Williams-Blangero, John Blangero, Carol K. Kasper, Laura Almasy, Tom E. Howard

Blood (2023) 142 (Supplement 1): 1247.

https://doi.org/10.1182/blood-2023-191140

Published: 2023

Journal Articles

Gene-Centric Association Scans of Pleiotropic Immune-Mediated Disease Genes in the PATH Study Identify Novel Determinants of Factor VIII Inhibitor Risk in Hemophilia-A Patients and Confirm Race as an Independent Predictor

Ruayda Bouls, Marcio A. Almeida, Vincent P. Diego, Bernadette W. Luu, Raja Rajalingam, Afshin Ameri, Kevin R. Viel, Meera Chitlur, Benjamin Kim, Miguel A. Escobar, Sarah Williams-Blangero, Carol K. Kasper, Laura Almasy, John Blangero, Tom E. Howard

Blood (2023) 142 (Supplement 1): 1246.

https://doi.org/10.1182/blood-2023-190094

Published: 2023

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

Hemophilia: a cautionary status report

Carol K. Kasper

Blood (2016) 127 (24): 2949–2950.

https://doi.org/10.1182/blood-2016-03-707117

Published: 2016

Journal Articles

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

Zuben E. Sauna, Jay N. Lozier, Carol K. Kasper, Chen Yanover, Timothy Nichols, Tom E. Howard

Blood (2015) 125 (2): 223–228.

https://doi.org/10.1182/blood-2013-12-530113

Published: 2015

Journal Articles

The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia A.

Tom E. Howard, MD, PhD, Shelley A. Cole, PhD, Carol K. Kasper, MD, Afshin Ameri, MD, Kavita Natarajan, MD, Raymond G. Watts, MD, Valrie A. Manard, RN, Shelley M. Nakaya, Christine L Kempton, MD, MSc, Martina Kennedy, DO, Benjamin Kim, MD, Rathi V. Iyer, MD, Laura Almasy, PhD

Blood (2009) 114 (22): 1301.

https://doi.org/10.1182/blood.V114.22.1301.1301

Published: 2009

Journal Articles

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

Tom E. Howard, MD, PhD, Kevin R. Viel, BS, Karl M. Fernstrom, BS, Seema Deshpande, PhD, Afshin Ameri, MD, M. Showkat Ali, PhD, Cynthia Channell, BS, Rathi V. Iyer, MD, Raymond G. Watts, MD, Charles Lutcher, MD, Shelley Nakaya, BS, Carol K. Kasper, MD, Arthur R. Thompson, MD, PhD, Thomas C. Abshire, MD, Laura Almasy, PhD

Blood (2006) 108 (11): 765.

https://doi.org/10.1182/blood.V108.11.765.765

Published: 2006

NARROW

Results from an Association-Scan of the Extended MHC-Class-II Region Using Novel Association-Based Statistical Methods Establish That DQ Allotypes and Race Independently Influence the Risk of Factor VIII Inhibitor Development in Hemophilia-A Patients

Gene-Centric Association Scans of Pleiotropic Immune-Mediated Disease Genes in the PATH Study Identify Novel Determinants of Factor VIII Inhibitor Risk in Hemophilia-A Patients and Confirm Race as an Independent Predictor

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Hemophilia: a cautionary status report

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia A.

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

Email alerts

ASH Publications

American Society of Hematology

Results from an Association-Scan of the Extended MHC-Class-II Region Using Novel Association-Based Statistical Methods Establish That DQ Allotypes and Race Independently Influence the Risk of Factor VIII Inhibitor Development in Hemophilia-A Patients

Gene-Centric Association Scans of Pleiotropic Immune-Mediated Disease Genes in the PATH Study Identify Novel Determinants of Factor VIII Inhibitor Risk in Hemophilia-A Patients and Confirm Race as an Independent Predictor

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Hemophilia: a cautionary status report

The intron-22–inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics

The Role of Immune-Response Gene Variants in Inhibitor Development in Black Patients with Hemophilia A.

Allelically Mismatched Replacement Therapy Due to Common African−Restricted Haplotypes of the Factor (F)VIII Protein May Underlie the Increased Incidence of FVIII Inhibitors Observed in Hemophilia−A Patients of African−Descent.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only